Dark Blue Therapeutics, a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen.
Working closely with BIA’s FTAC and HMRC, FTI Consulting have devoted a great deal of time interpreting the new legislation for qualifying overseas expenditure and guidance.
The first in a new series of skills webinars for the BIA Finance and Tax Community explored some of the most significant milestones in a company’s growth journey, with insights and reflections from experts with firsthand experience.
BIA thought leadership takes centre stage with two key reports published: last week saw the release of 'From innovation to impact: unlocking patient access to innovative rare disease medicines', and today 'UK cell and gene therapy: driving efficiencies and innovation' celebrates real-world UK success.
The 2025 Budget arrived at a pivotal moment for the UK’s life sciences and biotech sector, amid global instability, funding pressures, and potential policy shifts that could reshape the industry. Watch BIA's latest webinar recording as they unpack the key announcements, their impact, and how they align with the government’s Life Sciences Sector Plan and wider industrial strategy.
The BioIndustry Association (BIA) released From Innovation to Impact: Unlocking Patient Access to Innovative Rare Disease Medicines, calling for new pathway to give UK patients access to innovative rare disease medicines.
More than 110,000 people in the UK live with a muscle-wasting condition which gradually damages the way their muscles work. Over time, it stops them from living everyday life. In some cases, lives will be cut short. Through this partnership, the BIA will leverage the network it has fostered in the UK life sciences and biotech sector to support those affected by muscle-wasting conditions.
eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have entered a strategic collaboration to build a seamless, scalable pathway for cell and gene therapy development and manufacturing in the UK.
It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch.
Arecor Therapeutics plc has signed a co-development agreement with Sequel Med Tech LLC to combine AT278 (500U/mL) with Sequel’s twiist™ Automated Insulin Delivery (AID) system powered by Tidepool, and a royalty financing agreement with Ligand which will raise non-dilutive capital of up to $11 million (£8.2 million).
Parkinson’s UK awarded Cellestial Health £55,000 to continue exploring networks of brain cells called astrocytes that may hold answers for new treatments for Parkinson’s.
In this blog, Alan Griffith, Head of CDMO Global Operations, shares their achievements, priorities, and ambitions as a new member of the BIA community.
In this blog, Ivana Visnjic-Lynch, Marketing Manager at ZAGENO, discusses the race for breakthrough therapies and the need for effective R&D spend management which enables technology to unlock the future.
In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.
MDC and King’s College London have been awarded £400,000 funding from The Brain Tumour Charity to develop a groundbreaking new approach to treat glioblastoma, for patient benefit.
In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.
In this blog, Abby Clark builds on a round table the BIA hosted with Chi Onwurah MP and Newcastle life science companies to explore the landscape and the drivers which make the sector strong, yet undervalued.
